337 related articles for article (PubMed ID: 15828230)
1. [PPAR and diabetes].
Terauchi Y; Kadowaki T
Nihon Rinsho; 2005 Apr; 63(4):623-9. PubMed ID: 15828230
[TBL] [Abstract][Full Text] [Related]
2. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors.
Lee CH; Olson P; Evans RM
Endocrinology; 2003 Jun; 144(6):2201-7. PubMed ID: 12746275
[TBL] [Abstract][Full Text] [Related]
3. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
Gross B; Staels B
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
[TBL] [Abstract][Full Text] [Related]
4. [The structures and functions of peroxisome proliferator-activated receptors (PPARs)].
Takahashi N; Goto T; Kusudo T; Moriyama T; Kawada T
Nihon Rinsho; 2005 Apr; 63(4):557-64. PubMed ID: 15828220
[TBL] [Abstract][Full Text] [Related]
5. [PPARs: physiological functions and pharmacological roles of agonists in human diseases. Note II].
Filip-Ciubotaru F; Manciuc C; Grigore C; Foia L
Rev Med Chir Soc Med Nat Iasi; 2012; 116(1):240-7. PubMed ID: 23077903
[TBL] [Abstract][Full Text] [Related]
6. PPARs as therapeutic targets in cardiovascular disease.
van Bilsen M; van Nieuwenhoven FA
Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178
[TBL] [Abstract][Full Text] [Related]
7. Insulin resistance and PPAR insulin sensitizers.
Bhatia V; Viswanathan P
Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
9. [Nuclear receptors PPAR as a drug target in metabolic disorders].
Stolarczyk M; Gutman W; Derlacz RA
Postepy Biochem; 2011; 57(2):207-14. PubMed ID: 21913422
[TBL] [Abstract][Full Text] [Related]
10. [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].
Alemán G; Torres N; Tovar AR
Rev Invest Clin; 2004; 56(3):351-67. PubMed ID: 15612519
[TBL] [Abstract][Full Text] [Related]
11. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
Gervois P; Fruchart JC; Staels B
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
[TBL] [Abstract][Full Text] [Related]
12. Evolution of peroxisome proliferator-activated receptor agonists.
Chang F; Jaber LA; Berlie HD; O'Connell MB
Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
[TBL] [Abstract][Full Text] [Related]
13. [Nuclear Receptor PPARs and magnesium].
Fujii H
Clin Calcium; 2005 Nov; 15(11):52-64. PubMed ID: 16272614
[TBL] [Abstract][Full Text] [Related]
14. A nonthiazolidinedione peroxisome proliferator-activated receptor α/γ dual agonist CG301360 alleviates insulin resistance and lipid dysregulation in db/db mice.
Jeong HW; Lee JW; Kim WS; Choe SS; Shin HJ; Lee GY; Shin D; Lee JH; Choi EB; Lee HK; Yon GH; Cho B; Kim HR; Choi SH; Chung YS; Park SB; Chung H; Ro S; Kim JB
Mol Pharmacol; 2010 Nov; 78(5):877-85. PubMed ID: 20724462
[TBL] [Abstract][Full Text] [Related]
15. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
16. [The role of PPARs and their isoforms in metabolic disorders related to insulin resistance and diabetes].
Kravchenko NA; Iarmysh NV
Tsitol Genet; 2011; 45(3):68-78. PubMed ID: 21774406
[TBL] [Abstract][Full Text] [Related]
17. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptors and angiogenesis.
Biscetti F; Straface G; Pitocco D; Zaccardi F; Ghirlanda G; Flex A
Nutr Metab Cardiovasc Dis; 2009 Dec; 19(11):751-9. PubMed ID: 19628379
[TBL] [Abstract][Full Text] [Related]
19. PPAR ligands: are they potential agents for cardiovascular disorders?
Balakumar P; Rose M; Singh M
Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
[TBL] [Abstract][Full Text] [Related]
20. The peroxisome proliferator-activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis.
Hummasti S; Tontonoz P
Mol Endocrinol; 2006 Jun; 20(6):1261-75. PubMed ID: 16556736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
